|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.7000 - 2.7600|
|52 Week Range||1.3300 - 3.7400|
|Beta (3Y Monthly)||-0.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
MRI Interventions, Inc. (MRIC), a platform neurosurgery company with products designed for navigation in procedures for deep brain stimulation, ablation, aspiration and gene therapy, today announced preliminary and unaudited results for the quarter ended December 31, 2018, and expectations for fiscal 2019 revenue and cases. Revenue for the quarter ended December 31, 2018 is expected to be approximately $2.2 million, an increase of 30% from $1.7 million in the prior year fourth quarter. This increase was due primarily to a record 188 procedures using the company’s ClearPoint Neuro Navigation System in the 2018 fourth quarter.
MRI Interventions, Inc. (MRIC), a platform neurosurgery company with products designed for navigation in procedures involving deep-brain stimulation, ablation, and gene and drug delivery today announced FDA Clearance of the ClearPoint PURSUIT Neuro Aspiration system. The PURSUIT device was designed in collaboration with the Mayo Clinic and represents the first internally developed therapeutic product added to the MRI Interventions platform portfolio. The ClearPoint PURSUIT neuro aspiration device is indicated for the controlled aspiration of blood, clotted blood, cystic components of tumors, abscesses, colloid cysts, and cerebral spinal fluid using a manual syringe during the surgery of the ventricular system or cerebrum.
IRVINE, Calif., Nov. 12, 2018 -- MRI Interventions, Inc. (OTCQB: MRIC) (the “Company”) today announced financial results for its third fiscal quarter ended September 30, 2018..
MRI Interventions, Inc. (MRIC) today announced FDA clearance for the company’s latest software platform – ClearPoint® 2.0. The platform’s new features are designed to improve the clinical workflow and user experience of the company’s ClearPoint Neuro Navigation System, including enhanced functionality in areas of image fusion, volume of interest display and measurement, 3D image visualization and multi-trajectory planning. “ClearPoint 2.0 is a generational upgrade that has been years in the making,” commented Joe Burnett, President and CEO of MRI Interventions.
IRVINE, Calif., Nov. 05, 2018 -- MRI Interventions, Inc. (OTCQB:MRIC) announced that it will release financial results for its 2018 third quarter, which ended September 30,.
MRI Interventions (MRIC) congratulates Axovant Sciences Ltd. on the dosing of its first patient in a clinical study of AXO-Lenti-PD, also known as OXB-102, an investigational gene therapy for the treatment of Parkinson’s disease. AXO-Lenti-PD is a novel gene therapy that enables the expression of a set of three critical enzymes required for end-to-end dopamine synthesis in the brain. “We applaud this significant milestone for Axovant and their Parkinson’s disease program,” commented Zachary Carr, Portfolio Manager for Biologics and Drug Delivery at MRI Interventions.
MRI Interventions (MRIC) congratulates Monteris Medical on the FDA Clearance of its new NeuroBlate Optic Laser Probe. The new probe replaces a previous metallic thermocouple with a non-metallic fiber optic temperature sensor, eliminating risk of unintended probe heating and addressing prior concerns noted in an FDA field advisory notice. “We are thrilled to see one of the leaders in laser ablation surgery respond so quickly to the FDA requests and resolve any outstanding issues for this exciting product,” commented Joe Burnett, President and CEO at MRI Interventions.
MRI Interventions (MRIC) and CLS AB in Lund, Sweden, announced that the companies have signed an agreement granting MRI Interventions the exclusive right to distribute and sell CLS’s portfolio of products, including its TRANBERG® product line for high precision ablation, in the U.S. and Canada. This agreement includes interventional MR-guided procedures beyond the previously announced license agreement for spine and neurosurgery. “This is an exciting collaboration for MRI to execute on our four-pillar growth strategy,” commented Joe Burnett, President and CEO of MRI Interventions.
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / MRI Interventions, Inc. (OTCQB: MRIC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern ...
LOS ANGELES, CA / ACCESSWIRE / May 22, 2018 / MRI Interventions, Inc. (OTCQB: MRIC), today announced that Chief Executive Officer Joe Burnett will present at the 8th annual LD Micro Invitational on Tuesday, ...
NEW YORK, NY / ACCESSWIRE / March 27, 2018 / MRI Interventions, Inc. (OTCQB: MRIC), today announced that Joe Burnett, CEO, will present at the MicroCap Conference on April 9th and 10th at the Essex House ...